Cytoreductive Surgery in Ovarian Cancer

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2007 Dec 18

PMID 18083650

Citations 14

Authors

Christophe Pomel

Arjun Jeyarajah

David Oram

John Shepherd

David Milliken

Jacques Dauplat

Karina Reynolds

Affiliations

Soon will be listed here.

Abstract

As the overall prognosis for patients with ovarian cancer is poor, the management of this condition should be restricted to expert multi-disciplinary teams in gynaecological oncology. Apparent early stage ovarian cancer requires accurate and complete staging so that potential sites for metastases are not missed. Omitting adequate staging may have significant consequences including a negative impact on survival rates in young patients. The challenge with advanced ovarian cancer is to obtain a detailed appreciation of the extent of disease. This information allows treatment with primary chemotherapy if the cancer is considered to be inoperable and/or the general condition of the patient renders her unfit for appropriate surgery. Available data would suggest that a 5-year survival rate of 50% is only possible for those patients who have had complete cytoreduction of all tumour. Therefore, the best surgical option for patients with advanced ovarian cancer is a 'complete' primary surgical procedure that achieves complete clearance of the abdominal cavity rather than 'optimal' surgery that leaves tumour nodules up to 1 cm in diameter in situ in the patient.

Citing Articles

Ovarian Cancer Staging-How CT Scan Descriptions Differ from Surgical Findings.

Cwiertnia A, Borzyszkowska D, Golara A, Tuczynska N, Kozlowski M, Poncyljusz W J Clin Med. 2024; 13(15).

PMID: 39124826 PMC: 11312800. DOI: 10.3390/jcm13154560.

Phenome-wide association study of ovarian cancer identifies common comorbidities and reveals shared genetics with complex diseases and biomarkers.

Mulugeta A, Lumsden A, Madakkatel I, Stacey D, Lee S, Maenpaa J Cancer Med. 2024; 13(4):e7051.

PMID: 38457211 PMC: 10923028. DOI: 10.1002/cam4.7051.

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis.

Guarischi-Sousa R, Kroll J, Bonaldi A, Pierry P, Villela D, Souza C Diagnostics (Basel). 2023; 13(21).

PMID: 37958189 PMC: 10648202. DOI: 10.3390/diagnostics13213293.

Suppression of Metastatic Ovarian Cancer Cells by Bepridil, a Calcium Channel Blocker.

Zhang S, Kim D, Park M, Yin J, Park J, Chung Y Life (Basel). 2023; 13(7).

PMID: 37511982 PMC: 10381520. DOI: 10.3390/life13071607.

Role of perigastric arcade removal in serous epithelial ovarian cancers.

Kulkarni R, Mohapatra M, Nayak B, Samantaray S, Mohapatra J, Parija J Ecancermedicalscience. 2023; 17:1519.

PMID: 37113727 PMC: 10129396. DOI: 10.3332/ecancer.2023.1519.

References

Fagotti A, Fanfani F, Ludovisi M, Lo Voi R, Bifulco G, Testa A . Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol. 2005; 96(3):729-35. DOI: 10.1016/j.ygyno.2004.11.031. View

Trimbos J, Vergote I, Bolis G, Vermorken J, Mangioni C, Madronal C . Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003; 95(2):113-25. View

AVERETTE H, Hoskins W, Nguyen H, Boike G, Flessa H, Chmiel J . National survey of ovarian carcinoma. I. A patient care evaluation study of the American College of Surgeons. Cancer. 1993; 71(4 Suppl):1629-38. View

Chi D, Franklin C, Levine D, Akselrod F, Sabbatini P, Jarnagin W . Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004; 94(3):650-4. DOI: 10.1016/j.ygyno.2004.01.029. View

Leblanc E, Querleu D, Narducci F, Chauvet M, Chevalier A, Lesoin A . Surgical staging of early invasive epithelial ovarian tumors. Semin Surg Oncol. 2000; 19(1):36-41. DOI: 10.1002/1098-2388(200007/08)19:1<36::aid-ssu6>3.0.co;2-e. View

Nelson B, Rosenfield A, Schwartz P . Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol. 1993; 11(1):166-72. DOI: 10.1200/JCO.1993.11.1.166. View

Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Maggioni A . Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. J Clin Oncol. 2004; 23(4):751-8. DOI: 10.1200/JCO.2005.03.065. View

Bristow R, Chi D . Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006; 103(3):1070-6. DOI: 10.1016/j.ygyno.2006.06.025. View

Maggioni A, Benedetti Panici P, DellAnna T, Landoni F, Lissoni A, Pellegrino A . Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006; 95(6):699-704. PMC: 2360519. DOI: 10.1038/sj.bjc.6603323. View

10.

Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, du Bois A . Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.... Gynecol Oncol. 2007; 106(1):69-74. DOI: 10.1016/j.ygyno.2007.02.026. View

11.

Aletti G, Long H, Podratz K, Cliby W . Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?. Gynecol Oncol. 2006; 104(1):212-6. DOI: 10.1016/j.ygyno.2006.07.045. View

12.

Deffieux X, Castaigne D, Pomel C . Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer. 2006; 16 Suppl 1:35-40. DOI: 10.1111/j.1525-1438.2006.00323.x. View

13.

van der Burg M, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G . The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995; 332(10):629-34. DOI: 10.1056/NEJM199503093321002. View

14.

Chan J, Urban R, Hu J, Shin J, Husain A, Teng N . The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer. 2007; 96(12):1817-22. PMC: 2359970. DOI: 10.1038/sj.bjc.6603803. View

15.

Bristow R, Tomacruz R, Armstrong D, Trimble E, Montz F . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20(5):1248-59. DOI: 10.1200/JCO.2002.20.5.1248. View

16.

Mayer A, Chambers S, Graves E, Holm C, Tseng P, Nelson B . Ovarian cancer staging: does it require a gynecologic oncologist?. Gynecol Oncol. 1992; 47(2):223-7. DOI: 10.1016/0090-8258(92)90110-5. View

17.

Harmon R, Sugarbaker P . Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005; 2(1):3. PMC: 549516. DOI: 10.1186/1477-7800-2-3. View

18.

Benedetti Panici P, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E . Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005; 97(8):560-6. DOI: 10.1093/jnci/dji102. View

19.

Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P . Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg. 2003; 197(2):198-205. DOI: 10.1016/S1072-7515(03)00234-5. View

20.

Crawford S, Vasey P, Paul J, Hay A, Davis J, Kaye S . Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol. 2005; 23(34):8802-11. DOI: 10.1200/JCO.2005.02.1287. View